Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Autores de IIS La Fe

• 

  Miguel Ángel Martínez García

  Autor

Participantes ajenos a IIS La Fe

• Girón Moreno RM
• García-Clemente M
• Diab-Cáceres L
• Martínez-Vergara A
• Gómez-Punter RM

Grupos

• Neumología

  

  Leader

  Miguel Ángel Martínez García

Abstract

Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations.

Keywords

• CFTR modulator, RNA therapy, antibiotic, cystic fibrosis, editing gene, genetic therapy, inflammation, obstruction, treatment